Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches

Campos-da-Paz, Mariana; Dórea, José G.; Galdino, Alexsandro Sobreira; Lacava, Z.G.M.; Santos, Maria de Fátima Menezes Almeida

doi:10.2174/1872208312666180731104244

Cited by 120 publications

(72 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CEA is often secreted by tumors located in the digestive tract and is the most widely used CRC marker (27). CEA has good specificity and sensitivity for screening CRC and is a valuable tool for evaluating the prognosis of patients with CRC (28). The understanding of malignant tumors and their associated serum markers has increased in previous years, and this has indicated the potential of biomarkers in facilitating improvements to the diagnosis and evaluation of treatment effect and prognosis (29).…”

Section: Associations Between Biomarkers and Clinical Stage Of Diseasementioning

confidence: 99%

“…An overview of the association between biomarkers investigated in the present study and CRC.NSE NSE is a tumor marker widely used in the diagnosis of SCLC, but the association between(25,27,28) serum NSE levels and CRC are out of date and limited CEA CEA is an important prognostic factor and an indicator of the therapeutic effect and (12,13) recurrence in patients with CRC CA199Indications are that elevated levels may be informative for some CRC cancers (10,11) CA125CA125 is more sensitive for mucin-type ovarian cancer, and its combination with CA125 can (15) significantly improve the sensitivity of CRC detection in clinic CA242CA242 combined with other markers may improve early diagnosis of CRC, and the accuracy (16) of prognostic prediction in surgically treated patients with CRC NSE, neuron-specific enolase; CEA, carcinoembryonic antigen; CA199, cancer antigen 19-9; CA125, cancer antigen 125; CA242, cancer antigen 242; CRC, colorectal cancer; CI, confidence interval. rectal cancer, the Z values for NSE, CEA, CA19-9, CA125 and CA242 compared with the combination test were 4.997, 7.007, 10.123, 9.785 and 7.451, respectively (all P<0.01).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Hai

Shen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The present study investigated the value of combinations of five specific tumor biomarkers for the diagnosis of colorectal cancer (CRC): Neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen (CA)19-9, CA125 and CA242. Associations between these markers and clinicopathological characteristics (including the Tumor-Node-Metastasis stage) were also assessed. Serum levels of the 5 markers were compared between 358 patients with CRC and 298 healthy individuals (CRC and control group, respectively). The NSE concentration of the CRC group was significantly higher compared with the control. Furthermore, patients at clinical stage III+IV exhibited significantly higher NSE levels compared with those at stage I+II. The serum NSE level of N + patients was significantly higher compared with the Ngroup, and the NSE level of M 1 patients was significantly compared with the M 0 group. NSE level was also significantly associated with tumor stage, lymph node metastasis, distant metastasis and hematochezia. The area under the receiver operating characteristic curve (AUC) for NSE in CRC was 0.766, which was significantly higher than that of the other four markers, which ranged from 0.560-0.682. The AUC of NSE, CEA, CA19-9, CA125, CA242 combined was significantly higher compared with any of the markers individually (range, 0.796-0.858). Therefore, serum NSE may be a good clinical tool for the auxiliary diagnosis of colorectal cancer. Besides, the combination of NSE, CEA, CA19-9, CA125 and CA242 was significantly more sensitive compared with NSE alone. Thus, the combined detection of the 5 tumor markers may be more useful for the diagnosis of CRC.

show abstract

Section: Associations Between Biomarkers and Clinical Stage Of Diseasementioning

confidence: 99%

mentioning

confidence: 99%

Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Hai

Shen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Tumor markers refer to substances synthesized and secreted by tumor cells and released into blood, cells and body fluids, which can reflect the occurrence and development of tumor [20,23,24]. CEA is a proteoglycan complex produced by colorectal cancer, which is widely found in cancers of the digestive system [25,26]. CA24-2 is a kind of salivary acidified spingolipid glycosylated chain antigen, which is expressed in human pancreatic duct cells and colonic mucosal epithelial cells.…”

Section: Discussionmentioning

confidence: 99%

Clinical Diagnostic Value for Colorectal cancer Based on Serum CEA, CA24-2 and CA19-9

Rao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To explore the clinical value of a combined detection of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) for colorectal cancer (CRC).Methods The levels of serum tumor markers (CEA, CA24-2 and CA19-9) and clinicopathologic features in patients with colorectal cancer in Meizhou People's Hospital were evaluated. In addition, KRAS/NRAS, PIK3CA and BRAF mutations were detected in some patients with colorectal cancer.Results A total of 2,281 patients (1,420 males and 861 females) were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. The levels of CEA, CA24-2 and CA19-9 in colorectal cancer group was significantly higher than control group. The sensitivities of three individual markers were lower than 30%, which individual sensitivity of the tumor markers sorted in descending order were CEA> CA19-9> CA24-2. The specificities of three individual markers were more than 92%, and the specificity sorted in descending order were CA24-2> CA19-9> CEA. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 -0.28CEA -0.11 CA242 + 0.001 CA199)/ (1+ Exp (-5.47 -0.28CEA -0.11 CA242 + 0.001 CA199)). There were no significant differences in age, gender, histology type, differentiation, depth of invasion and TNM stage between mutations in KRAS/NRAS , BRAF and PIK3CA genes or not, respectively.Conclusions Serum CEA, ca24-2, and ca19-9 are valuable noninvasive indicators for the detection and screening of patients with early colon cancer. We need to look for other, more sensitive tumor markers.

show abstract

“…Tumor markers refer to substances synthesized and secreted by tumor cells and released into blood, cells and body uids, which can re ect the occurrence and development of tumor [28,31,32]. CEA is a proteoglycan complex produced by colorectal cancer, which is widely found in cancers of the digestive system [33,34]. CA24-2 is a kind of salivary acidi ed spingolipid glycosylated chain antigen, which is expressed in human pancreatic duct cells and colonic mucosal epithelial cells.…”

Section: Discussionmentioning

confidence: 99%

Clinical Diagnostic Value for Colorectal Cancer Based on Serum CEA, CA24-2 and CA19-9

Rao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background To explore the clinical value of a combined detection of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) for colorectal cancer (CRC). Methods The levels of serum tumor markers (CEA, CA24-2 and CA19-9) and clinical characteristics in patients with colorectal cancer were evaluated. In addition, KRAS/NRAS/PIK3CA/BRAF mutations were detected in some patients with colorectal cancer. Results A total of 2,281 patients were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. The levels of CEA, CA24-2 and CA19-9 in colorectal cancer group was significantly higher than control group. The sensitivities of three individual markers were lower than 30%, which individual sensitivity of the tumor markers sorted in descending order was CEA>CA19-9>CA24-2. The specificities of three individual markers were more than 92%, and the specificity sorted in descending order was CA24-2>CA19-9>CEA. The combination of CEA+CA19-9+CA24-2 ranked the highest in sensitivity index and specificity index for colorectal cancer diagnosis. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 - 0.28CEA - 0.11 CA242 + 0.001 CA199)/ (1+ Exp (-5.47 - 0.28CEA - 0.11 CA242 + 0.001 CA199)). There were no significant differences in age, gender, histology type, differentiation, depth of invasion and TNM stage between mutations in KRAS/NRAS, BRAF and PIK3CA genes or not, respectively. Conclusions Serum CEA, CA24-2, and CA19-9 are valuable noninvasive indicators for prediction the risk of colorectal cancer. We need to look for other, more sensitive tumor markers.

show abstract

Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches

Cited by 120 publications

References 0 publications

Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Clinical Diagnostic Value for Colorectal cancer Based on Serum CEA, CA24-2 and CA19-9

Clinical Diagnostic Value for Colorectal Cancer Based on Serum CEA, CA24-2 and CA19-9

Contact Info

Product

Resources

About